XTLB on Nasdaq
XTL Bio
Clinical stage biopharmaceutical company.1
Price unavailable
Last updated Oct 19, 2026.
Overview
1993Founded1
Compare with Scienture Holdings, Inc., Pasithea Therapeutics Corp. or MEDICINOVA INC, or pick any stock.
- TickerXTLB on Nasdaq1
- Industrybiopharmaceutical1
- HeadquartersRa'anana1
- Founded inIsrael1
- Websitewww.xtlbio.com
- Legal formlimited company, public company1
- Listed onNasdaq (XTLB), Tel Aviv Stock Exchange (XTLB)1
- Incorporated inIsrael4
- Business addressXtl Biopharmaceuticals Ltd, C/O Alston & Bird Llp, 90 Park Avenue, New York, Ny 100164
- Filer categoryNon-accelerated filer4
- LEI529900NDDXEAPTUTXP413
- StatusActive3
- LEI statusLapsed (not renewed)3
- Registered address5 HaCharoshet St., 4365603 Raanana, Israel3
- Registered withIsraeli Corporations Authority (Department of Justice), 5200394703
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
0.7%Gross margin5
-481.6%Operating margin5
-227.7%Net margin5
-18.9%Return on equity5
-$1.7MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Cost of revenue64¢$448.0K
- Research and development14¢$98.0K
- Interest4¢$28.0K
- Income tax18¢$130.0K
Out of $451.0K in revenue.5 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development expenses | -$28.0K | -$16.0K | -$31.0K |
| General and administrative expenses | -$1.4M | -$759.0K | -$734.0K |
| Other expenses | -$223.0K | ||
| Operating loss | -$1.7M | -$775.0K | -$765.0K |
| Change in fair value of financial instruments | $1.1M | $926.0K | |
| Change in fair value of marketable securities | $5.0K | $167.0K | -$1.0M |
| Change in fair value of convertible loan from shareholder | -$54.0K | ||
| Interest expenses | -$7.0K | ||
| Other finance income | $60.0K | $34.0K | $41.0K |
| Other finance expenses | -$177.0K | -$112.0K | -$36.0K |
| Finance income (expenses), net | $929.0K | $1.0M | -$1.0M |
| Loss before income taxes | -$759.0K | $240.0K | -$1.8M |
| Profit (loss) from continuing operations | -$759.0K | $240.0K | -$1.8M |
| Loss from discontinued operations, net of tax | -$6.2M | -$1.3M | |
| Net loss for the year | -$7.0M | -$1.0M | -$1.8M |
| Profit (loss) from continuing operations (in Dollars per share) | -$0.00 | $0.00 | -$0.00 |
| Diluted profit (loss) from continuing operations (in Dollars per share) | -$0.00 | $0.00 | -$0.00 |
| Loss from discontinued operations (in Dollars per share) | -$0.01 | -$0.00 | |
| Diluted loss from discontinued operations (in Dollars per share) | -$0.01 | -$0.00 | |
| Total basic and diluted loss per share (in Dollars per share) | -$0.01 | -$0.00 | -$0.00 |
| Total diluted loss per share (in Dollars per share) | -$0.01 | -$0.00 | -$0.00 |
| Weighted average number of issued ordinary shares (in Shares) | 896.2M shares | 673.0M shares | 544.9M shares |
| Diluted weighted average number of ordinary shares (in Shares) | 896.2M shares | 673.0M shares | 544.9M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 7 quarters (quarterly), latest first.9
| Period ending | 2025-12-31 | 2025-09-30 | 2024-12-31 | 2024-09-30 | 2024-07-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $76.0K | $371.0K | |||
| Marketable securities InterCure Ltd. | $772.0K | ||||
| Trade receivable (net of allowance for credit losses of $0 and $36 at December 31, 2025 and 2024, respectively) | $99.0K | ||||
| Prepaid expenses and other current assets | $22.0K | $98.0K | |||
| Warrants, net | $68.0K | ||||
| Total current assets | $166.0K | $1.3M | |||
| Fixed assets, net | $187.0K | $167.0K | |||
| Intangible assets, net | $3.8M | $3.6M | |||
| Goodwill | $3.2M | $3.2M | |||
| Long-term bank deposit | $14.0K | ||||
| Total Non-current assets | $7.2M | ||||
| Total assets | $166.0K | $8.6M | $5.8M | ||
| Loans and credit from banking corporations | $138.0K | $163.0K | |||
| Accounts payable | $151.0K | $790.0K | |||
| Warrants, net | $1.3M | ||||
| Convertible loan from shareholder | $269.0K | ||||
| Total current liabilities | $420.0K | $2.2M | |||
| Warrants | $689.0K | ||||
| Deferred tax liability, net | $219.0K | ||||
| Total Non-Current liabilities | $908.0K | ||||
| Share capital - ordinary shares of NIS 0.1 par value: Authorized December 31, 2025 and 2024 - 1,450,000,000; Issued and outstanding - 946,243,356 on December 31, 2025 and 881,385,256 on December 31, 2024; | $25.1M | $23.1M | |||
| Additional paid in capital | $140.2M | $1.1M | $141.3M | ||
| Reserve from transactions with non-controlling interests | $20.0K | $20.0K | |||
| Accumulated deficit | -$165.6M | -$159.0M | |||
| Total equity | -$254.0K | $5.4M | |||
| Total liabilities and equity | $166.0K | $8.6M | |||
| Trade receivable net of allowance for credit losses | $0 | $36.0K | |||
| Ordinary shares, par value (in New Shekels per share) | 0.10 ILS | 0.10 ILS | |||
| Ordinary shares, shares authorized (in Shares) | 1.4B shares | 1.4B shares | |||
| Ordinary shares, shares issued (in Shares) | 946.2M shares | 881.4M shares | |||
| Ordinary shares, shares outstanding (in Shares) | 946.2M shares | 881.4M shares |
| Period ending | 2025-12-31 | 2025-09-30 | 2024-12-31 | 2024-09-30 | 2024-07-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $76.0K | $371.0K | $1.4M | $2.1M | |||
| Marketable securities InterCure Ltd. | $772.0K | $605.0K | $1.6M | ||||
| Trade receivable (net of allowance for credit losses of $0 and $36 at December 31, 2025 and 2024, respectively) | $99.0K | ||||||
| Prepaid expenses and other current assets | $22.0K | $98.0K | |||||
| Warrants, net | $68.0K | ||||||
| Total current assets | $166.0K | $1.3M | |||||
| Fixed assets, net | $187.0K | $167.0K | |||||
| Intangible assets, net | $3.8M | $3.6M | |||||
| Goodwill | $3.2M | $3.2M | |||||
| Long-term bank deposit | $14.0K | ||||||
| Total Non-current assets | $7.2M | ||||||
| Total assets | $166.0K | $8.6M | $5.8M | ||||
| Loans and credit from banking corporations | $138.0K | $163.0K | |||||
| Accounts payable | $151.0K | $790.0K | |||||
| Warrants, net | $1.3M | ||||||
| Convertible loan from shareholder | $269.0K | ||||||
| Total current liabilities | $420.0K | $2.2M | |||||
| Warrants | $689.0K | ||||||
| Deferred tax liability, net | $219.0K | ||||||
| Total Non-Current liabilities | $908.0K | ||||||
| Share capital - ordinary shares of NIS 0.1 par value: Authorized December 31, 2025 and 2024 - 1,450,000,000; Issued and outstanding - 946,243,356 on December 31, 2025 and 881,385,256 on December 31, 2024; | $25.1M | $23.1M | |||||
| Additional paid in capital | $140.2M | $1.1M | $141.3M | ||||
| Reserve from transactions with non-controlling interests | $20.0K | $20.0K | |||||
| Accumulated deficit | -$165.6M | -$159.0M | |||||
| Total equity | -$254.0K | $5.4M | $2.2M | $4.0M | |||
| Total liabilities and equity | $166.0K | $8.6M | |||||
| Trade receivable net of allowance for credit losses | $0 | $36.0K | |||||
| Ordinary shares, par value (in New Shekels per share) | 0.10 ILS | 0.10 ILS | |||||
| Ordinary shares, shares authorized (in Shares) | 1.4B shares | 1.4B shares | |||||
| Ordinary shares, shares issued (in Shares) | 946.2M shares | 881.4M shares | |||||
| Ordinary shares, shares outstanding (in Shares) | 946.2M shares | 881.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Loss for the Year | -$7.0M | -$1.0M | -$1.8M |
| Adjustments to reconcile net income (loss) to net cash used in operating activities (a) | $5.9M | -$591.0K | $1.1M |
| Net cash used in operating activities | -$1.0M | -$1.6M | -$707.0K |
| Purchase of fixed assets | -$54.0K | ||
| Interest from bank deposit | $34.0K | $41.0K | |
| Investment in long-term deposits | -$14.0K | ||
| Acquisition of subsidiary, consolidated for the first time (see Note 5) | -$410.0K | ||
| Loan provided to subsidiary prior to acquisition | -$400.0K | ||
| Proceeds from sale of marketable securities | $777.0K | ||
| Loan to former subsidiary | -$250.0K | ||
| Cash and cash equivalents of deconsolidated subsidiary (see note 6) | -$5.0K | ||
| Net cash provided by (used in) investing activities | $522.0K | -$844.0K | $41.0K |
| Loan repayment | -$13.0K | ||
| Issuance of shares and warrants | $1.5M | ||
| Shareholder loan | $208.0K | ||
| Net cash provided by financing activities | $208.0K | $1.4M | |
| Decrease in cash and cash equivalents | -$295.0K | -$1.0M | -$666.0K |
| Losses from exchange rate differences on cash and cash equivalents | -$15.0K | -$27.0K | |
| Depreciation and amortization | $199.0K | ||
| Change in deferred taxes | -$130.0K | ||
| Revaluation of marketable securities | -$5.0K | -$167.0K | $1.0M |
| Revaluation of warrants | -$1.1M | -$926.0K | |
| Share-based payment expense | $346.0K | $264.0K | $3.0K |
| Impairment loss on intangible assets | $223.0K | ||
| Bad debt loss | $308.0K | ||
| Exchange rate differences | -$35.0K | $14.0K | $27.0K |
| Interest income | -$60.0K | -$34.0K | -$41.0K |
| Interest expenses | $7.0K | ||
| Revaluation of convertible loan | $54.0K | ||
| Loss from disposal/deconsolidation of subsidiary | $6.2M | ||
| Net income and expenses not involving operating cash flows | $5.9M | -$780.0K | $1.0M |
| Decrease (increase) in prepaid expenses and other current assets | $28.0K | -$58.0K | $45.0K |
| Decrease in trade receivables | $157.0K | $39.0K | |
| Increase (decrease) in accounts payable | -$187.0K | $208.0K | $19.0K |
| Net operating asset and liability | -$2.0K | $189.0K | $64.0K |
| Net cash provided by (used in) operating activities | $5.9M | -$591.0K | $1.1M |
No quarter-by-quarter statement was filed.
Leadership
Who has led XTL Bio, and when. Pick a name to see everywhere that person has worked.
Chief executive
1995200020052010201520202025
- Chief executive officerRon Bentsur Aug 17, 2006 to Aug 21, 200711
Board members and other officers (8)
- Director of FinanceWilliam Kessler Aug 22, 2007 to Aug 22, 200712
- Board memberFain Osnat Hillel Mar 23, 2026 to now13
- Board memberMichael S. Weiss Aug 26, 2008 to Nov 4, 200814
- Board memberBen-Zion Weiner Sep 4, 2008 to Nov 4, 200815
- Board memberJennifer L. Good Nov 4, 2008 to Nov 4, 200816
- Board memberKenneth J. Zuerblis Nov 4, 2008 to Nov 4, 200817
- Board memberSamuel Rudman Nov 4, 2008 to Nov 4, 200818
- Board memberWilliam James Kennedy Nov 4, 2008 to Nov 4, 200819
Timeline
Filings
71 filings to the SEC since October 2021: 5 annual reports, 2 insider forms, 64 other. The latest 20:
- Oct 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 21, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 30, 202620-F ANNUAL REPORT EDGAR
- Jun 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Apr 30, 2026NT 20-F NOTIFICATION OF LATE FILING EDGAR
- Apr 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Mar 23, 20263 EDGAR
- Mar 23, 20263 EDGAR
- Mar 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Mar 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Feb 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Feb 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Feb 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Feb 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
The 71 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Rhumbline Advisers | 6,228 | $17.0K | 0.0% | +241 |
| GAMMA Investing LLC | 1,213 | $3.3K | 0.0% | −2,175 |
| UBS Group AG | 125 | $341 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.xtlbio.com1
- WikidataQ96482054
- SEC EDGARCIK 1023549
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataXTL Bio on Wikidata
- 2SEC EDGARXTL Bio filings on SEC EDGAR
- 3
- 4SEC EDGARXTL Bio filings on SEC EDGAR
- 5SEC EDGARXTL Bio 10-K for fiscal 2024
- 6SEC EDGARXTL Bio 10-K for fiscal 2018
- 7SEC EDGARXTL Bio 10-K for fiscal 2019
- 8SEC EDGARXTL Bio 10-K for fiscal 2020
- 9
- 10SEC EDGARXTL Bio 10-K for fiscal 2018
- 11SEC EDGARRon Bentsur, Chief executive officer
- 12SEC EDGARWilliam Kessler, Director of Finance
- 13SEC EDGARFain Osnat Hillel, Board member
- 14SEC EDGARMichael S. Weiss, Board member
- 15SEC EDGARBen-Zion Weiner, Board member
- 16SEC EDGARJennifer L. Good, Board member
- 17SEC EDGARKenneth J. Zuerblis, Board member
- 18SEC EDGARSamuel Rudman, Board member
- 19SEC EDGARWilliam James Kennedy, Board member